Icovamenib (BMF-219)
Type 2 Diabetes (Insulin-Deficient)
Key Facts
About Biomea Fusion
Biomea Fusion is a clinical-stage biotechnology company dedicated to developing covalent small molecule therapies for diabetes and obesity, with the ambitious goal of curing disease. Its lead asset, icovamenib, is a novel oral menin inhibitor designed to regenerate pancreatic beta cells and is advancing through multiple Phase II trials in type 1 and type 2 diabetes. The company's strategy leverages its integrated covalent inhibitor platform to create highly selective, durable therapies, positioning it to address significant unmet needs in large metabolic markets. Key near-term catalysts include topline 26-week data from two Phase II studies in type 2 diabetes expected in Q4 2026.
View full company profileAbout Biomea Fusion
Biomea Fusion is a clinical-stage biotechnology company dedicated to developing covalent small molecule therapies for diabetes and obesity, with the ambitious goal of curing disease. Its lead asset, icovamenib, is a novel oral menin inhibitor designed to regenerate pancreatic beta cells and is advancing through multiple Phase II trials in type 1 and type 2 diabetes. The company's strategy leverages its integrated covalent inhibitor platform to create highly selective, durable therapies, positioning it to address significant unmet needs in large metabolic markets. Key near-term catalysts include topline 26-week data from two Phase II studies in type 2 diabetes expected in Q4 2026.
View full company profileAbout Biomea Fusion
Biomea Fusion is a clinical-stage biotechnology company dedicated to developing covalent small molecule therapies for diabetes and obesity, with the ambitious goal of curing disease. Its lead asset, icovamenib, is a novel oral menin inhibitor designed to regenerate pancreatic beta cells and is advancing through multiple Phase II trials in type 1 and type 2 diabetes. The company's strategy leverages its integrated covalent inhibitor platform to create highly selective, durable therapies, positioning it to address significant unmet needs in large metabolic markets. Key near-term catalysts include topline 26-week data from two Phase II studies in type 2 diabetes expected in Q4 2026.
View full company profileAbout Biomea Fusion
Biomea Fusion is a clinical-stage biotechnology company dedicated to developing covalent small molecule therapies for diabetes and obesity, with the ambitious goal of curing disease. Its lead asset, icovamenib, is a novel oral menin inhibitor designed to regenerate pancreatic beta cells and is advancing through multiple Phase II trials in type 1 and type 2 diabetes. The company's strategy leverages its integrated covalent inhibitor platform to create highly selective, durable therapies, positioning it to address significant unmet needs in large metabolic markets. Key near-term catalysts include topline 26-week data from two Phase II studies in type 2 diabetes expected in Q4 2026.
View full company profile